Cabaletta Bio Inc Total Assets
Cabaletta Bio Inc total assets. Based on the latest financial reports, Cabaletta Bio Inc (CABA) holds total assets worth $256.73 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CABA market cap for the company's overall valuation and market capitalisation.
Total Assets of Cabaletta Bio Inc (2017–2025)
Total assets of Cabaletta Bio Inc from 2017 to 2025. This chart illustrates how Cabaletta Bio Inc's total assets have evolved over time, based on quarterly financial data. See Cabaletta Bio Inc stock price for real-time trading data and today's change.
Cabaletta Bio Inc - Asset Composition Analysis
Cabaletta Bio Inc Total Assets Breakdown (December 2025)
Cabaletta Bio Inc total assets breakdown as of December 2025. Cabaletta Bio Inc's total assets of $256.73 Million consist of 84.1% current assets and 15.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Cabaletta Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CABA current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cabaletta Bio Inc's current assets represent 84.1% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 50.3% of total assets in 2025, down from 100.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cabaletta Bio Inc Competitors by Total Assets
Key competitors of Cabaletta Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Cabaletta Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.79 | 4.78 | 20.07 |
| Quick Ratio | 5.79 | 4.78 | 20.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $191.12 Million | $156.87 Million | $114.83 Million |
Cabaletta Bio Inc - Advanced Valuation Insights
This section examines the relationship between Cabaletta Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.34 |
| Latest Market Cap to Assets Ratio | 1.46 |
| Asset Growth Rate (YoY) | -10.8% |
| Total Assets | $165.08 Million |
| Market Capitalization | $240.75 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cabaletta Bio Inc's assets above their book value (1.46x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cabaletta Bio Inc's assets decreased by 10.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cabaletta Bio Inc (2017–2025)
The table below shows the annual total assets of Cabaletta Bio Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $165.08 Million | -10.79% |
| 2024-12-31 | $185.05 Million | -27.05% |
| 2023-12-31 | $253.65 Million | +116.85% |
| 2022-12-31 | $116.97 Million | -7.42% |
| 2021-12-31 | $126.34 Million | +10.12% |
| 2020-12-31 | $114.72 Million | -18.90% |
| 2019-12-31 | $141.47 Million | +313.96% |
| 2018-12-31 | $34.17 Million | +3417300.00% |
| 2017-12-31 | $1.00K | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more